Cargando…

Pharmacological counseling in hepatotoxicity induced by macitentan and selexipag: a case report

BACKGROUND: Pulmonary arterial hypertension is a progressive, debilitating condition characterized by increased resistance in the pulmonary arterial circulation. Current treatments for pulmonary arterial hypertension include endothelin receptor antagonists such as bosentan, sitaxentan, ambrisentan,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lattanzio, Mariangela, Ferrari, Marco, Martini, Stefano, Ceriani, Francesca, Imporzani, Andrea, Marino, Franca, De Ponti, Roberto, Cosentino, Marco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9578229/ https://www.ncbi.nlm.nih.gov/pubmed/36258237 http://dx.doi.org/10.1186/s13256-022-03571-9

Ejemplares similares

Triple oral combination therapy with macitentan, riociguat, and selexipag for pulmonary arterial hypertension
por: Momoi, Mizuki, et al.
Publicado: (2021)

Effects of Dual Initial Combination Therapy With Macitentan Plus Riociguat or Macitentan Plus Selexipag on Hemodynamics in Patients With Pulmonary Arterial Hypertension (SETOUCHI-PH Study)　― Protocol of a Multicenter Randomized Control Trial ―
por: Akagi, Satoshi, et al.
Publicado: (2021)

Effects of Cannabidiol on Innate Immunity: Experimental Evidence and Clinical Relevance
por: Martini, Stefano, et al.
Publicado: (2023)

Understanding the Pharmacology of COVID-19 mRNA Vaccines: Playing Dice with the Spike?
por: Cosentino, Marco, et al.
Publicado: (2022)

Selexipag for pulmonary arterial hypertension
Publicado: (2021)

Assessment of right ventricle in pulmonary arterial hypertension with three-dimensional echocardiography and cardiovascular magnetic resonance
por: Lattanzio, Mariangela, et al.
Publicado: (2021)

Coronavirus Disease-19 Vaccines Best Reflect Effective Pharmaceuticals
por: Cosentino, Marco, et al.
Publicado: (2021)

Macitentan for the treatment of pulmonary arterial hypertension
por: Kholdani, Cyrus A, et al.
Publicado: (2014)

Selexipag in the management of pulmonary arterial hypertension: an update
por: Coghlan, J Gerry, et al.
Publicado: (2019)

Selexipag for the treatment of chronic thromboembolic pulmonary hypertension
por: Ogo, Takeshi, et al.
Publicado: (2022)

Dopaminergic regulation of inflammation and immunity in Parkinson's disease: friend or foe?
por: Furgiuele, Alessia, et al.
Publicado: (2023)

Macitentan in pulmonary arterial hypertension: The SERAPHIN trial
por: Said, Karim
Publicado: (2014)

Macitentan in the treatment of pulmonary hypertension in Gaucher’s disease
por: Taylan, Gökay, et al.
Publicado: (2020)

Hemodynamic and clinical effects of selexipag in children with pulmonary hypertension
por: Rothman, Abraham, et al.
Publicado: (2020)

Immunomodulatory Potential of Cannabidiol in Multiple Sclerosis: a Systematic Review
por: Furgiuele, Alessia, et al.
Publicado: (2021)

The PROB-PD trial: a pilot, randomised, placebo-controlled study protocol to evaluate the feasibility and potential efficacy of probiotics in modulating peripheral immunity in subjects with Parkinson’s disease
por: Martini, Stefano, et al.
Publicado: (2023)

Selexipag in the treatment of pulmonary arterial hypertension: design, development, and therapy
por: Hardin, Elizabeth Ashley, et al.
Publicado: (2016)

Baseline history of patients using selexipag for pulmonary arterial hypertension
por: Highland, Kristin B., et al.
Publicado: (2019)

Use of selexipag in a teenage patient with pulmonary arterial hypertension
por: Bravo-Valenzuela, Nathalie Jeanne Magioli, et al.
Publicado: (2021)

Effect of quercetin on the pharmacokinetics of selexipag and its active metabolite in beagles
por: Luo, Shun-bin, et al.
Publicado: (2021)

Transitioning selexipag to oral treprostinil in patients with pulmonary artery hypertension
por: Arevalo, Carlo, et al.
Publicado: (2022)

Macitentan: An important addition to the treatment of pulmonary arterial hypertension
por: Khadka, Anjan, et al.
Publicado: (2015)

Clinical Pharmacokinetics and Pharmacodynamics of the Endothelin Receptor Antagonist Macitentan
por: Sidharta, P. N., et al.
Publicado: (2015)

The use of Macitentan in Fontan circulation: a case report
por: Demetriades, Polyvios, et al.
Publicado: (2017)

Pharmacokinetics and Tolerability of the Novel Oral Prostacyclin IP Receptor Agonist Selexipag
por: Kaufmann, Priska, et al.
Publicado: (2015)

Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension
por: Gaine, Sean, et al.
Publicado: (2017)

Transition from parenteral prostacyclins to selexipag: safety and feasibility in selected patients
por: Aldweib, Nael, et al.
Publicado: (2021)

Case Report: Selexipag in pediatric pulmonary hypertension: Initiation, transition, and titration
por: Faircloth, Jenna M., et al.
Publicado: (2023)

Cost-effectiveness analysis of selexipag for the combined treatment of pulmonary arterial hypertension
por: Dong, Wenxing, et al.
Publicado: (2023)

Swift and Complete Healing of Digital Ulcers after Macitentan Treatment
por: Giner Serret, Emilio
Publicado: (2016)

Benefits from the Early Initiation of Macitentan for Pulmonary Arterial Hypertension
por: Jung, Hae Ok
Publicado: (2018)

Safety and tolerability of macitentan in the management of pulmonary arterial hypertension: an update
por: Wong, Alexandra K, et al.
Publicado: (2019)

Initial combination therapy of macitentan and tadalafil in pulmonary arterial hypertension
por: Sitbon, Olivier, et al.
Publicado: (2020)

The Endothelin Receptor Antagonist Macitentan Inhibits Human Cytomegalovirus Infection
por: Landázuri, Natalia, et al.
Publicado: (2021)

Effects of bergapten on the pharmacokinetics of macitentan in rats both in vitro and in vivo
por: Xu, Jia, et al.
Publicado: (2023)

Efficacy and safety of macitentan for pulmonary hypertension: A meta‐analysis
por: Du, Dan, et al.
Publicado: (2023)

The spike hypothesis in vaccine-induced adverse effects: questions and answers
por: Cosentino, Marco, et al.
Publicado: (2022)

In response to Detection of SARS-CoV-2 IgA and IgG in human milk and breastfeeding infant stool 6 months after maternal COVID-19 vaccination
por: Cosentino, Marco, et al.
Publicado: (2023)

Functional single nucleotide polymorphisms in dopaminergic receptors D2 predict clinical response to Cariprazine
por: De Pieri, Marco, et al.
Publicado: (2023)

Effects of selexipag and its active metabolite in contrasting the profibrotic myofibroblast activity in cultured scleroderma skin fibroblasts
por: Cutolo, Maurizio, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_dsltcm9vv6cd90rl12mfkas0jo